Bicara Therapeutics Inc. Financing Cash Flow
Bicara Therapeutics Inc. (BCAX) reported Financing Cash Flow of $165.68 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-11
- Bicara Therapeutics Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $2.33M, a 1627.41% increase year-over-year.
- Bicara Therapeutics Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $163.34M, a 35409.78% increase year-over-year.
- Bicara Therapeutics Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $31.23M.
- Bicara Therapeutics Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $436.00K, a 99.87% decline year-over-year.
- Bicara Therapeutics Inc. net cash provided by (used in) financing activities for fiscal 2025 was $32.26M, a 90.34% decline from fiscal 2024.
- Bicara Therapeutics Inc. net cash provided by (used in) financing activities for fiscal 2024 was $334.03M, a 22.58% increase from fiscal 2023.
- Bicara Therapeutics Inc. net cash provided by (used in) financing activities for fiscal 2023 was $272.50M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $165.68M 10-Q · filed 2026-08-11 | $196.91M derived: sum of 3 quarters · filed 2026-08-11 | $197.34M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $163.34M 10-Q · filed 2026-05-11 | $194.57M derived: sum of 2 quarters · filed 2026-05-11 | $195.01M derived: sum of 3 quarters · filed 2026-05-11 | $195.15M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $31.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $31.67M derived: sum of 2 quarters · filed 2026-03-30 | $31.80M derived: sum of 3 quarters · filed 2026-08-11 | $32.26M 10-K · filed 2026-03-30 |
| 2025-09-30 | $436.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $571.00K derived: sum of 2 quarters · filed 2026-08-11 | $1.03M 10-Q · filed 2025-11-10 | $56.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $135.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $595.00K 10-Q · filed 2026-08-11 | -$380.00K derived: sum of 3 quarters · filed 2026-08-11 | $333.75M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $460.00K 10-Q · filed 2026-05-11 | -$515.00K derived: sum of 2 quarters · filed 2026-05-11 | $333.62M derived: sum of 3 quarters · filed 2026-05-11 | $334.35M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$975.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $333.16M derived: sum of 2 quarters · filed 2026-03-30 | $333.89M derived: sum of 3 quarters · filed 2026-03-30 | $334.03M 10-K · filed 2026-03-30 |
| 2024-09-30 | $334.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $334.87M derived: sum of 2 quarters · filed 2025-11-10 | $335.01M 10-Q · filed 2025-11-10 | $529.71M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $734.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $871.00K 10-Q · filed 2025-08-12 | $195.57M derived: sum of 3 quarters · filed 2025-08-12 | |
| 2024-03-31 | $137.00K 10-Q · filed 2025-05-13 | $194.84M derived: sum of 2 quarters · filed 2025-05-13 | ||
| 2023-12-31 | $194.70M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $272.50M 10-K · filed 2025-03-27 | ||
| 2023-09-30 | $77.79M 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B |